CN1326850C - 三环类法尼基蛋白转移酶抑制剂 - Google Patents

三环类法尼基蛋白转移酶抑制剂 Download PDF

Info

Publication number
CN1326850C
CN1326850C CNB99816206XA CN99816206A CN1326850C CN 1326850 C CN1326850 C CN 1326850C CN B99816206X A CNB99816206X A CN B99816206XA CN 99816206 A CN99816206 A CN 99816206A CN 1326850 C CN1326850 C CN 1326850C
Authority
CN
China
Prior art keywords
dichloromethane
title compound
stirred
methanol
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB99816206XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1334811A (zh
Inventor
A·G·塔维拉斯
R·J·多尔
A·B·库珀
J·A·菲雷拉
T·古兹
A·K·马拉姆斯
D·F·拉内
V·M·吉里杰瓦尔拉汉
A.阿方索
C·J·阿基
J·赵
C·阿瓦雷兹
J·M·凯利
T·拉瓦尼
J·A·德塞
J·J·-S·王
J·维恩斯泰恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN1334811A publication Critical patent/CN1334811A/zh
Application granted granted Critical
Publication of CN1326850C publication Critical patent/CN1326850C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Electroluminescent Light Sources (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB99816206XA 1998-12-18 1999-12-16 三环类法尼基蛋白转移酶抑制剂 Expired - Fee Related CN1326850C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21639898A 1998-12-18 1998-12-18
US09/216,398 1998-12-18
US09/216398 1998-12-18

Publications (2)

Publication Number Publication Date
CN1334811A CN1334811A (zh) 2002-02-06
CN1326850C true CN1326850C (zh) 2007-07-18

Family

ID=22806914

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB99816206XA Expired - Fee Related CN1326850C (zh) 1998-12-18 1999-12-16 三环类法尼基蛋白转移酶抑制剂

Country Status (20)

Country Link
EP (1) EP1140902A1 (enExample)
JP (1) JP2002533336A (enExample)
KR (1) KR20010081116A (enExample)
CN (1) CN1326850C (enExample)
AR (1) AR021718A1 (enExample)
AU (1) AU776558B2 (enExample)
BR (1) BR9916314A (enExample)
CA (1) CA2354779A1 (enExample)
CO (1) CO5160350A1 (enExample)
CZ (1) CZ20011950A3 (enExample)
HU (1) HUP0202152A2 (enExample)
IL (1) IL143408A0 (enExample)
NO (1) NO20012961L (enExample)
NZ (1) NZ511878A (enExample)
PE (1) PE20001342A1 (enExample)
PL (1) PL348293A1 (enExample)
SK (1) SK7592001A3 (enExample)
TR (1) TR200101755T2 (enExample)
WO (1) WO2000037459A1 (enExample)
ZA (1) ZA200104233B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0202152A2 (en) 1998-12-18 2002-10-28 Schering Corp Tricyclyc farnesyl protein transferase inhibitors
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
US6645966B2 (en) 2001-01-22 2003-11-11 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
AU2002257114A1 (en) * 2001-04-06 2002-10-21 Schering Corporation Treatment of malaria with farsenyl protein transferase inhibitors
CA2590979A1 (en) 2004-12-13 2006-06-22 Schering Corporation Novel farnesyl protein transferase inhibitors and their use to treat cancer
JP2008523148A (ja) * 2004-12-14 2008-07-03 シェーリング コーポレイション ファルネシルプロテイントランスフェラーゼインヒビターおよび増殖性疾患を処置するための方法
CA2637572A1 (en) * 2006-01-19 2007-07-26 Schering Corporation Piperazine derivatives as farnesyl protein transferase inhibitors
MX2016012060A (es) 2014-03-19 2017-01-19 Viamet Pharmaceuticals Inc 2-(2,4-difluorofenil)-1,1-difluoro-1-(5-sustituido-piridin-2-il)- 3-(1h-tetrazol-1-il)propan-2-oles y procesos para su preparacion.
BR112016021257B1 (pt) * 2014-03-19 2021-03-02 Viamet Pharmaceuticals (NC), Inc. 2-(2,4- difluorofenil-1,1-diflúor-1-(5-substituído-piridin-2-il)-3- (1h-tetrazol-1-il)propan-2-óis e processos para preparação e uso dos mesmos

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998004545A1 (en) * 1996-07-31 1998-02-05 Schering Corporation Novel tricyclic n-cyanoimines useful as inhibitors of farnesyl-protein transferase
US5801175A (en) * 1995-04-07 1998-09-01 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111235A (en) 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
IL117798A (en) 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
US5712280A (en) * 1995-04-07 1998-01-27 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
ZA985203B (en) * 1997-06-17 1999-01-05 Schering Corp Compounds useful for inhibition of farnesyl protein transferase
HUP0202152A2 (en) 1998-12-18 2002-10-28 Schering Corp Tricyclyc farnesyl protein transferase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801175A (en) * 1995-04-07 1998-09-01 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
WO1998004545A1 (en) * 1996-07-31 1998-02-05 Schering Corporation Novel tricyclic n-cyanoimines useful as inhibitors of farnesyl-protein transferase

Also Published As

Publication number Publication date
PL348293A1 (en) 2002-05-20
IL143408A0 (en) 2002-04-21
SK7592001A3 (en) 2002-03-05
ZA200104233B (en) 2002-08-22
NZ511878A (en) 2003-10-31
CZ20011950A3 (cs) 2001-12-12
KR20010081116A (ko) 2001-08-27
AR021718A1 (es) 2002-07-31
JP2002533336A (ja) 2002-10-08
AU776558B2 (en) 2004-09-16
HUP0202152A2 (en) 2002-10-28
CA2354779A1 (en) 2000-06-29
WO2000037459A1 (en) 2000-06-29
TR200101755T2 (tr) 2001-09-21
EP1140902A1 (en) 2001-10-10
BR9916314A (pt) 2001-10-02
PE20001342A1 (es) 2000-12-09
CO5160350A1 (es) 2002-05-30
AU2030700A (en) 2000-07-12
NO20012961D0 (no) 2001-06-15
NO20012961L (no) 2001-08-16
CN1334811A (zh) 2002-02-06

Similar Documents

Publication Publication Date Title
US6372747B1 (en) Farnesyl protein transferase inhibitors
US6300338B1 (en) Tricyclic carbamate compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US5880128A (en) Carbonyl piperazinyl and piperidinyl compounds
US5712280A (en) Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
EP0723538B1 (en) Tricyclic carbamate compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US6362188B1 (en) Farnesyl protein transferase inhibitors
US6492381B1 (en) Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
KR20010081115A (ko) 파르네실 단백질 트랜스퍼라제 억제제
CN1326850C (zh) 三环类法尼基蛋白转移酶抑制剂
KR20030034161A (ko) 파르네실 단백질 트랜스퍼라제 억제제인 트리사이클릭항종양 화합물
EP0989983B1 (en) Benzpyrido cycloheptane compounds useful for inhibition of farnesyl protein transferase
WO2003072549A1 (en) Farnesyl protein transferase inhibitors as antitumor agents
US6800636B2 (en) Farnesyl protein transferase inhibitors
JP2001500508A (ja) ファルネシルタンパク質トランスフェラーゼの阻害に有用な置換ベンゾシクロヘプタピリジン誘導体
KR20000036110A (ko) 파르네실 단백질 전이효소의 억제에 유용한 삼환식 화합물
JP2913082B2 (ja) バソプレシン拮抗剤及びオキシトシン拮抗剤
JPH10182459A (ja) cGMP分解酵素阻害剤
JP2002533455A (ja) ファルネシルタンパク質トランスフェラーゼの新規なインヒビター
KR20010013826A (ko) 신규한 파네실-단백질 트랜스퍼라제의 트리사이클릭설폰아미드 억제제
MXPA01006241A (en) Tricyclic farnesyl protein transferase inhibitors
KR20000068550A (ko) 파르네실 단백질 전이효소의 억제에 유용한 화합물

Legal Events

Date Code Title Description
C06 Publication
C10 Entry into substantive examination
PB01 Publication
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070718

Termination date: 20111216